secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001823239-22-000056
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated
----------------------------------------------------------------------------

- Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.
- Adjusted EBITDA $132.5M (69% margin), down from $154.9M prior year.
- Nucleic Acid Production revenue $174.9M, down 4% YoY; COVID-19 CleanCap revenue estimated $126.5M.
- Biologics Safety Testing revenue $16.4M, down 1% YoY.
- FY2022 guidance updated for revenue, Adjusted EBITDA, and Adjusted EPS; specific figures not provided in excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/0001823239-22-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/mrvi-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001823239-22-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer